Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial
Primary result · QFR increaseResult — go to the resultOdds ratio 1.7 95% CI 0.9–3.0Authors' conclusion
Treatment of AMI patients with alirocumab versus placebo for 1 year resulted in a significant regression in angiographic DS%, whereas no overall improvement of coronary haemodynamics was observed.
Study context
- Population
- Acute myocardial infarction (AMI) patients with non-IRA ≥2.0 mm and 3D-QCA DS% >25%193 with serial quantitative flow ratio (QFR)/3D-QCA analysed
- Participants
- 300 patients
- Comparison
- Alirocumab vs placebo on top of rosuvastatin
- Alirocumabn = 94
- Placebon = 99reference
- Primary endpoint
- Number of patients with a mean QFR increase
- Follow-up
- 1 year
Methodological detailsprespecified substudy
- Prespecified substudy
Primary result
QFR increase
Odds ratio
1.7
95% CI 0.9–3.0
P = 0.076
Events by treatment group
Alirocumabvs Placebo
OR 1.7 (95% CI 0.9–3.0); P = 0.076
As reported in the abstract
Secondary outcomes
| Outcome | Alirocumab | Placebo | Difference (%) (95% CI) | P value | |
|---|---|---|---|---|---|
| Change in 3D-QCA DS% · 1 year | mean decrease 1.03 (SD 7.28) % | mean increase 1.70 (SD 8.27) % | −2.50 (−4.43 to −0.57) | P = 0.011 | |
| −6−4−202Difference, % (linear scale) |
Original publication
Impact of alirocumab on plaque regression and haemodynamics of non-culprit arteries in patients with acute myocardial infarction: a prespecified substudy of the PACMAN-AMI trial. EuroIntervention. Published 17 July 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →